
Alok Bhagwat Joshi
About Alok Bhagwat Joshi
Data last updated:
Alok Bhagwat Joshi was a Director at Pharmarack Technologies Private Limited (2022–2024), Director at Trikaal Mediinfotech Private Limited (2022–2024) and Director at Lakme Lever Private Limited (2015–2018), and held 3 more directorships. The companies operate in Healthcare, Information Technology and Health and Wellness Services.
Previous companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 29 Jul 2022 | 2015 | ₹45.34 Cr (FY 2024) | Active | |
| Director | 12 Sep 2022 | 2007 | ₹39.7 Lakh (FY 2025) | Active | |
| Director | 31 Mar 2015 | 2008 | ₹401 Cr (FY 2026) | Active | |
| Director | 31 Mar 2015 | 1994 | ₹1,627 Cr (FY 2025) | Active | |
| Director | 31 Mar 2021 | 2021 | ₹1.05 Cr (FY 2024) | Under Liquidation | |
| Director | 24 Aug 2022 | 2007 | ₹20.07 Cr (FY 2022) | Amalgamated |
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Alok Bhagwat Joshi
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Alok Bhagwat Joshi
Alok Bhagwat Joshi was first appointed on 31 Mar 2015 as Director at Lakme Lever Private Limited. The most recent appointment on record is 12 Sep 2022 at Trikaal Mediinfotech Private Limited.
Alok Bhagwat Joshi held 6 earlier board appointments: Pharmarack Technologies Private Limited (Director, 29 Jul 2022 to 22 Apr 2024); Trikaal Mediinfotech Private Limited (Director, 12 Sep 2022 to 22 Apr 2024); Lakme Lever Private Limited (Director, 31 Mar 2015 to 30 Aug 2018); Unilever Industries Private Limited (Director, 31 Mar 2015 to 20 Nov 2018); Jech India Private Limited (Director, 31 Mar 2021 to 30 Jun 2022); and 1 more.